Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials

M (Melissa) Vos; Stefan Sleijfer; S Litiere; N Touati; F Duffaud; WT van der Graaf; H Gelderblom

doi:10.1080/0284186x.2019.1581376

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials

M (Melissa) Vos
, Stefan Sleijfer
, S Litiere
, N Touati
, F Duffaud
, WT van der Graaf
, H Gelderblom

Research output: Contribution to journal › Article › Academic › peer-review

13 Citations (Scopus)

45 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	872-879
Number of pages	8
Journal	Acta Oncologica
Volume	58
Issue number	6
DOIs	https://doi.org/10.1080/0284186x.2019.1581376
Publication status	Published - 2019

Research programs

EMC MM-03-86-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/0284186x.2019.1581376

RePub-117762-OA.pdfFinal published version, 1.76 MB

http://hdl.handle.net/1765/117762

Cite this

Vos, M., Sleijfer, S., Litiere, S., Touati, N., Duffaud, F., van der Graaf, WT., & Gelderblom, H. (2019). Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. Acta Oncologica, 58(6), 872-879. https://doi.org/10.1080/0284186x.2019.1581376

@article{3ebebb98189543278d5e1f871737fe57,

title = "Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials",

author = "Vos, \{M (Melissa)\} and Stefan Sleijfer and S Litiere and N Touati and F Duffaud and \{van der Graaf\}, WT and H Gelderblom",

year = "2019",

doi = "10.1080/0284186x.2019.1581376",

language = "Undefined/Unknown",

volume = "58",

pages = "872--879",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "6",

}

Vos, M, Sleijfer, S, Litiere, S, Touati, N, Duffaud, F, van der Graaf, WT & Gelderblom, H 2019, 'Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials', Acta Oncologica, vol. 58, no. 6, pp. 872-879. https://doi.org/10.1080/0284186x.2019.1581376

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. / Vos, M (Melissa); Sleijfer, Stefan; Litiere, S et al.
In: Acta Oncologica, Vol. 58, No. 6, 2019, p. 872-879.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials

AU - Vos, M (Melissa)

AU - Sleijfer, Stefan

AU - Litiere, S

AU - Touati, N

AU - Duffaud, F

AU - van der Graaf, WT

AU - Gelderblom, H

PY - 2019

Y1 - 2019

U2 - 10.1080/0284186x.2019.1581376

DO - 10.1080/0284186x.2019.1581376

M3 - Article

SN - 0284-186X

VL - 58

SP - 872

EP - 879

JO - Acta Oncologica

JF - Acta Oncologica

IS - 6

ER -

Vos M, Sleijfer S, Litiere S, Touati N, Duffaud F, van der Graaf WT et al. Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. Acta Oncologica. 2019;58(6):872-879. doi: 10.1080/0284186x.2019.1581376